^
    11ms
    The distribution of FGFR3 alterations in diffuse gliomas and their relation with patient prognosis (ChiCTR2400094890)
    P=N/A, N=1200, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFRvIII mutation
    1year
    Fusion transcriptome landscape in Glioblastoma (SNO 2024)
    Comprehensive molecular profiling reveals that approximately 10% of IDH WT GBMs carry oncogenic fusions that may be therapeutic targets. Broad spectrum of observed fusions underscores the need for novel clinical trial designs to allow efficient enrollment for prospective testing of potential targeted agents.
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CDK4 (Cyclin-dependent kinase 4) • CAPZA2 (Capping Actin Protein Of Muscle Z-Line Subunit Alpha 2) • SEC61G (SEC61 Translocon Subunit Gamma) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    TP53 mutation • EGFR mutation • NTRK1 fusion • NTRK2 fusion • MET amplification • EGFR amplification • ALK fusion • ROS1 fusion • MET mutation • EGFRvIII mutation • FGFR3 fusion • IDH wild-type • EGFR fusion
    |
    MI Tumor Seek™
    over1year
    Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Duke University | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFRvIII mutation
    over1year
    Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma. (PubMed, Neurooncol Adv)
    Total cfDNA may also assist with prognostic information. Further studies are needed to validate these findings and the clinical role of ctDNA in glioma.
    Journal • Liquid biopsy • Circulating tumor DNA • Biopsy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    EGFR mutation • IDH1 mutation • EGFRvIII mutation • TERT mutation
    2years
    Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. (PubMed, Cancer Commun (Lond))
    Our findings not only uncovered the mechanism of metabolic reprogramming in EGFR-activated GBM but also provided a combinatorial therapeutic strategy for clinical GBM management.
    Journal
    |
    ACSL3 (Acyl-CoA Synthetase Long Chain Family Member 3)
    |
    EGFR mutation • EGFR amplification • EGFR overexpression • EGFRvIII mutation
    |
    Tagrisso (osimertinib) • temozolomide • MK-2206 • lovastatin
    2years
    Efficacy of WSD0922-Fu in osimertinib-resistant NSCLC with central nervous system (CNS) metastases – Updates from the dose escalation cohort of a first-in-human phase 1 clinical trial (MC1914) (SNO 2023)
    All patients with HGA received prior radiation and temozolomide. Furthermore, prolonged stable disease (9 cycles) was observed in a patient with EGFRvIII mutant GBM. Expansion cohorts are in progress to optimize WSD0922-Fu dose and schedule for future phase 2 development.
    Clinical • P1 data
    |
    EGFR mutation • EGFRvIII mutation
    |
    Tagrisso (osimertinib) • temozolomide • WSD0922
    2years
    Improved overall survival of recurrent glioblastoma (GBM) patients with EGFR amplification and EGFR vIII mutations treated with osimertinib: a retrospective review (SNO 2023)
    We conducted a retrospective review of rGBM patients with EGFR amplification and EGFRvIII mutations who received osimertinib in addition to other therapies such as bevacizumab, irinotecan, tumor-treating fields, and salvage radiation at recurrence. Despite the limitations of a retrospective study and small sample size, osimertinib is a promising targeted therapy for rGBM. Further research is warranted in a clinical trial to evaluate this treatment prospectively.
    Retrospective data • Review
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation • IDH wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • irinotecan
    2years
    Targeting Cancer Stem Cells with a CDK2 Inhibitor in Glioblastoma (SNO 2023)
    Importantly, we found that the compound inhibited the self-renewal and growth of BTSCs in EGFRvIII subtype of BTSCs. This research has led to future investigation on in vivo assessment of this CDK2 inhibitor in combination with ionizing radiation and chemotherapy in preclinical models of GB.
    Cancer stem
    |
    OSMR (Oncostatin M Receptor)
    |
    EGFR mutation • EGFRvIII mutation
    2years
    Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients. (PubMed, Neurooncol Adv)
    Further analysis revealed genetic enrichment that enables stratification of responders from nonresponders prior to dacomitinib treatment as well as following administration. This study demonstrates that genetic composition analysis of serum EVs may aid in therapeutic stratification to identify patients with dacomitinib-responsive GBM.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation
    |
    Vizimpro (dacomitinib)
    over2years
    Evaluating Gene Fusions in Solid Tumors by Next- Generation Sequencing: A Tertiary Centre Experience (AMP Europe 2023)
    "Gene fusions represent crucial targets in the context of precision medicine. NGS testing for fusion detection not only allows analysis of multiple targets but also saves time and material. The identification of novel fusions in this study also highlights the potential for future therapeutic targets."
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ETV6 (ETS Variant Transcription Factor 6) • LMNA (Lamin A/C) • DCTN1 (Dynactin Subunit 1) • AGK (Acylglycerol Kinase) • SDC4 (Syndecan 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • NTRK1 fusion • MET exon 14 mutation • ROS1 positive • EGFRvIII mutation • FGFR1 fusion • FGFR3 fusion • LMNA-NTRK1 fusion • SDC4-ROS1 fusion • NTRK fusion
    |
    SOPHiA DDM™ Solid Tumor Plus Solution